Our
Technologies
External and implantable neuromodulation platforms built to deliver ARC Therapy.
Our Mission
Driven to restore
Movement
Function
Independence
in people with spinal cord injury
Join our Patient Registry if you are interested in our clinical trials
Discover our Therapy
Discover our Therapy
-
ARC Therapy is targeted stimulation of the spinal cord designed to restore upper and lower limb movement and other functions, such as blood pressure regulation, after SCI.
Our external ARCEX System is built to non-invasively deliver ARCEX Therapy, and our implantable ARCIM and ARCBCI™ Systems are built to minimally invasively deliver ARCIM Therapy.These benefits have been observed in published pre-clinical and human feasibility studies.
Watch how it works
Clinical results may vary.
External Platform
External Platform
-
The first system approved for non-invasive spinal cord stimulation for people with spinal cord injury (SCI).
The ARCEX System is indicated to improve hand sensation and strength for people with a chronic cervical spinal cord injury.*The US FDA granted the ARCEX platform Breakthrough Device Designations for improvement of upper and lower limb function, bladder control, regulation of blood pressure, and alleviation of spasticity in people with spinal cord injury.
Learn more
Implantable Platform
Implantable Platform
-
Investigational, neurostimulation platform to minimally invasively deliver targeted ARCIM Therapy to the spinal cord.
The US FDA awarded the ARCIM platform Breakthrough Device Designations for restoration of leg motor function, blood pressure regulation, trunk stabilization, bladder control, and alleviation of spasticity in people with spinal cord injury.
Learn more
Implantable Platform
Implantable Platform
-
Investigational system that pairs ARCIM Therapy with a brain-computer interface (BCI) to restore thought-driven movement of the upper and lower limbs.
In partnership with EPFL and CEA-Clinatec, in 2021 we successfully implanted an investigational BCI in a human to augment our ARCIM Therapy with thought-driven movement of the legs after paralysis. The approach was published in Nature in May 2023.
Learn more
With a European Innovation Council grant to study restoration of thought-driven arm and hand movement after SCI, an additional human was implanted with ARCIM Therapy + BCI in 2023. Three more people are scheduled to participate in the study in 2024.
Read our Publications
Please complete this form to
contact us or receive updates
The ONWARD® Medical ARCEX® System is cleared for use only in the United States. ONWARD ARCIM® and ARCBCI™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
*The ARCEX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).